Respect for Persons: Belmont Principle & Rules

Respect for persons is a foundational ethical principle in human subjects research requiring investigators to treat individuals as autonomous agents and protect those with diminished autonomy. First articulated in the 1979 Belmont Report and codified under 45 CFR 46, it dictates that participation in research must be voluntary, informed, and free from coercion.

What it is and who runs it

Respect for persons is one of the three core ethical principles established in The Belmont Report (issued April 18, 1979) by the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. Codified under Title 45, Part 46 of the Code of Federal Regulations (45 CFR 46, the Common Rule) and FDA regulations under 21 CFR 50, regulatory oversight is directed by the Office for Human Research Protections (OHRP) within the U.S. Department of Health and Human Services (HHS). At the institutional level, governance is executed by Institutional Review Boards (IRBs). Internationally, the principle is embedded in Canada’s Tri-Council Policy Statement (TCPS 2, Chapter 1) and the World Medical Association’s Declaration of Helsinki.

The Belmont Report articulates two fundamental ethical convictions:

Individuals should be treated as autonomous agents: Autonomous persons can deliberate about personal goals and act on those deliberations. Investigators must respect considered choices without interference, provided actions do not harm others.
Persons with diminished autonomy are entitled to protection: Individuals who are immature, incapacitated, or subject to severe constraints lack full self-determination and require explicit safeguards against exploitation.

Eligibility and populations covered

Under 45 CFR 46.102, respect for persons applies to living individuals from whom an investigator obtains identifiable private information, biospecimens, or data through intervention or interaction. Cohorts are classified into four operational tiers:

Autonomous adults: Competent individuals of legal age capable of evaluating study parameters independently.
Children and minors: Under 45 CFR 46 Subpart D, researchers must obtain the minor’s assent alongside permission from parents or legal guardians.
Cognitively impaired individuals: Persons with psychiatric illness, dementia, or acute cognitive trauma. Research requires consent from a legally authorized representative (LAR) and participant assent when possible.
Dependent or constrained populations: Prisoners (governed by 45 CFR 46 Subpart C), patients in critical care, students, and employees. Under 45 CFR 46.111(b), IRBs require additional safeguards against coercion and undue influence.

What it funds or requires

Respect for persons is a regulatory compliance mandate rather than a grant-making program. Compliance is required for federally supported research awards and institutional ethics clearance. As described on the official OHRP guidance pages as of November 2026, the principle requires three essential consent elements:

1. Information

Investigators must disclose study purposes, procedures, foreseeable risks, potential benefits, alternatives, and confidentiality measures as mandated by 45 CFR 46.116. Under 45 CFR 46.116(a)(5)(i), consent forms must begin with a concise summary of key information explaining why someone might or might not want to participate.

2. Comprehension

Information must be adapted to the participant’s language, reading level, and cognitive capacity (45 CFR 46.116(a)(3)). Legalistic liability waivers are prohibited. High-risk protocols often require interactive comprehension checks before enrollment.

3. Voluntariness

Agreement must be free of coercion (threats of harm) and undue influence (excessive compensation or exploitation of authority). Participants retain the right to withdraw at any time without penalty or loss of entitled benefits.

Application or compliance steps

Investigators must complete six operational compliance steps to meet 45 CFR 46.111 and 46.116 requirements:

Assess participant vulnerability: Identify whether the target cohort involves minors, decisionally impaired adults, or dependent groups.
Draft plain-language consent forms: Author readable consent documents featuring the required concise key-information summary.
Establish assent and LAR procedures: Define surrogate consent pathways under applicable law when enrolling individuals with diminished autonomy.
Obtain IRB approval: Submit consent forms, recruitment plans, and compensation schedules to the IRB for formal review.
Administer voluntary consent: Conduct an unhurried consent discussion, verify comprehension, and document participant agreement before any study procedures.
Manage ongoing consent: Communicate newly discovered risks and honor participant withdrawal requests immediately without penalty.

Typical timeline phases

Compliance progresses through five distinct research lifecycle phases:

Phase 1: Pre-Submission Preparation: Drafting consent forms, completing CITI ethics training, and establishing vulnerability safeguards.
Phase 2: Formal IRB Review: IRB assessment of consent clarity, voluntariness, and recruitment safeguards under 45 CFR 46.111.
Phase 3: Recruitment and Enrollment: Conducting consent discussions, verifying comprehension, and securing documented consent or assent prior to research activities.
Phase 4: Ongoing Monitoring and Re-Consent: Re-consenting participants when protocols change, new risks emerge, or enrolled minors reach legal age.
Phase 5: Study Closure and Record Retention: Archiving signed consent records for statutory retention periods and executing data withdrawal requests.

Common mistakes

Common compliance failures cited by IRBs and auditors include:

Treating consent as a one-time signature: Reducing an ongoing communicative dialogue to a static paperwork formality.
Excessive compensation: Offering payments that induce economically vulnerable subjects to overlook substantial clinical risks.
Conflating child assent with parental permission: Assuming parental agreement nullifies a child’s active refusal in non-beneficial studies.
Invalid surrogate consent: Accepting consent from relatives who lack legal authorization under state or local law.
Hurried administration: Administering consent forms immediately prior to surgery without sufficient deliberation time.
Distorting risk-benefit analysis: Downplaying experimental hazards or exaggerating therapeutic prospects during recruitment.

Related programs and ethical frameworks

Respect for persons is operationalized across multiple research ethics frameworks:

Framework / Standard	Oversight Authority	Primary Scope	Core Autonomy Mechanism	Protections for Diminished Autonomy
Belmont Report (1979)	National Commission / HHS	U.S. biomedical and behavioral research	Three-part consent: Information, Comprehension, Voluntariness	Surrogate permission and protective exclusion from non-beneficial risks
45 CFR 46 Subpart A	Office for Human Research Protections (OHRP)	Federally funded U.S. human subjects research	46.116 mandatory consent elements and concise key summary	46.111(b) safeguards for children, prisoners, and impaired individuals
45 CFR 46 Subpart D	HHS / OHRP	Research involving children	Child assent paired with parental permission (46.408)	Limits on allowable research risk categories (46.404-46.407)
TCPS 2 (2022)	Panel on Research Ethics (CIHR, NSERC, SSHRC)	Canadian institutional human research	Article 3.1: Free, informed, and ongoing consent; data withdrawal rights	Decision-making capacity assessments and authorized third parties
Declaration of Helsinki (2024)	World Medical Association (WMA)	Physicians and medical research globally	Freely given informed consent documented in plain language	Surrogate consent permitted only when condition necessitates enrollment
21 CFR 50	U.S. Food and Drug Administration (FDA)	FDA-regulated trials of drugs and devices	Legally effective documented consent (50.20, 50.25)	Emergency research exceptions (50.24) and pediatric safeguards

Frequently asked questions

What are the two core moral convictions of respect for persons?

The Belmont Report defines two ethical convictions: first, that individuals must be treated as autonomous agents capable of self-determination; and second, that persons with diminished autonomy are entitled to additional safeguards against harm and exploitation.

How does respect for persons translate into informed consent?

Informed consent is the direct practical application of respect for persons. It operationalizes autonomy through three elements: adequate information about the study, participant comprehension of the facts, and voluntary agreement free from coercion or undue influence.

Who qualifies as having diminished autonomy in research?

Diminished autonomy applies to individuals whose decision-making capacity or freedom is restricted. This includes children, persons with cognitive or psychiatric impairments, individuals in emergency care, and institutionalized populations such as prisoners.

What is the difference between assent and consent?

Consent is a legally valid agreement provided by an adult with decision-making capacity. Assent is an affirmative agreement provided by a minor or decisionally impaired individual who cannot legally consent, which must be accompanied by surrogate permission.

How does the revised Common Rule support participant comprehension?

Under 45 CFR 46.116(a)(5)(i), consent forms must begin with a concise summary of key information that highlights study purpose, duration, procedures, risks, and benefits, enabling participants to understand core considerations before reading extensive disclosures.

Can participants withdraw consent after research begins?

Yes. Voluntariness dictates that participants may withdraw from a study at any time without penalty, loss of entitlements, or compromise to their ongoing medical care or institutional status.

Sources

National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. DHEW Publication No. (OS) 78-0012, April 18, 1979.
U.S. Department of Health and Human Services. Title 45, Code of Federal Regulations, Part 46: Protection of Human Subjects (Common Rule). Sections 46.111, 46.116, Subparts B, C, and D. Legal Information Institute, Cornell Law School, verified November 8, 2026. https://www.law.cornell.edu/cfr/text/45/46.116
Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada, and Social Sciences and Humanities Research Council. Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans (TCPS 2 – 2022). Chapter 1 and Chapter 3. Interagency Advisory Panel on Research Ethics, verified November 8, 2026. https://ethics.gc.ca/eng/tcps2-eptc2_2022_chapter1-chapitre1.html
World Medical Association. Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. Adopted June 1964; revised October 2024, verified November 8, 2026. https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/
U.S. Food and Drug Administration. Title 21, Code of Federal Regulations, Part 50: Protection of Human Subjects. Sections 50.20, 50.24, and 50.25. Electronic Code of Federal Regulations, verified November 8, 2026.